Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations

Cancer

Volumn 122, Issue 1, 2016, Pages 20-33

  Bosse, Kristopher R ^a   Maris, John M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anaplastic lymphoma kinase (ALK); clonal evolution; genome wide association studies; neuroblastoma; pediatric; v myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN)

Indexed keywords

ALLELE; CANCER GENETICS; CANCER PROGNOSIS; CHROMOSOME REARRANGEMENT; CLONAL EVOLUTION; COPY NUMBER VARIATION; DNA DETERMINATION; FAMILIAL CANCER; GENE DELETION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; NEUROBLASTOMA; NONHUMAN; ONCOGENE; ONCOGENE C MYB; PATIENT MONITORING; POINT MUTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; PROCEDURES; TRENDS;

ANIMALS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; NEUROBLASTOMA;

EID: 84948822795     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29706     Document Type: Review

References (126)

1. Maris JM,. Recent advances in neuroblastoma. N Engl J Med. 2010; 362: 2202-2211.
2. National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. SEER Database. Available at: http://seer.cancer.gov. Accessed January 15, 2015.
3. Maris JM, Hogarty MD, Bagatell R, Cohn SL,. Neuroblastoma. Lancet. 2007; 369: 2106-2120.
4. Smith MA, Seibel NL, Altekruse SF, et al., Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010; 28: 2625-2634.
5. Evans AE, Silber JH, Shpilsky A, D'Angio GJ,. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996; 14: 2504-2510.
6. Cole WH, Everson TC,. Spontaneous regression of cancer: preliminary report. Ann Surg. 1956; 144: 366-383.
7. Yu AL, Gilman AL, Ozkaynak MF, et al., Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010; 363: 1324-1334.
8. Matthay KK, Reynolds CP, Seeger RC, et al., Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol. 2009; 27: 1007-1013.
9. Kushner BH, Cheung NK, LaQuaglia MP, et al., Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol. 1996; 14: 373-381.
10. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM,. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224: 1121-1124.
11. Seeger RC, Brodeur GM, Sather H, et al., Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313: 1111-1116.
12. Attiyeh EF, London WB, Mosse YP, et al., Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005; 353: 2243-2253.
13. Bown N, Cotterill S, Lastowska M, et al., Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340: 1954-1961.
14. Bourhis J, Benard J, DeVathaire F, et al., Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Prog Clin Biol Res. 1991; 366: 107-113.
15. Look AT, Hayes FA, Shuster JJ, et al., Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991; 9: 581-591.
16. George RE, London WB, Cohn SL, et al., Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005; 23: 6466-6473.
17. Cohn SL, Pearson AD, London WB, et al., The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009; 27: 289-297.
18. Monclair T, Brodeur GM, Ambros PF, et al., The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009; 27: 298-303.
19. Diskin SJ, Capasso M, Schnepp RW, et al., Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012; 44: 1126-1130.
20. Wang K, Diskin SJ, Zhang H, et al., Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature. 2011; 469: 216-220.
21. Capasso M, Devoto M, Hou C, et al., Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009; 41: 718-723.
22. Mosse YP, Laudenslager M, Longo L, et al., Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455: 930-935.
23. Maris JM, Mosse YP, Bradfield JP, et al., Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008; 358: 2585-2593.
24. Janoueix-Lerosey I, Lequin D, Brugieres L, et al., Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455: 967-970.
25. Capasso M, Diskin S, Cimmino F, et al., Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res. 2014; 74: 6913-6924.
26. Diskin SJ, Capasso M, Diamond M, et al., Rare variants in TP53 and susceptibility to neuroblastoma [serial online]. J Natl Cancer Inst. 2014; 106: dju047.
27. Capasso M, Diskin SJ, Totaro F, et al., Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility. Carcinogenesis. 2013; 34: 605-611.
28. Latorre V, Diskin SJ, Diamond MA, et al., Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans. Cancer Epidemiol Biomarkers Prev. 2012; 21: 658-663.
29. Nguyen le B, Diskin SJ, Capasso M, et al., Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility loci [serial online]. PLoS Genet. 2011; 7: e1002026.
30. Diskin SJ, Hou C, Glessner JT, et al., Copy number variation at 1q21.1 associated with neuroblastoma. Nature. 2009; 459: 987-991.
31. Russell MR, Penikis A, Oldridge DA, et al., CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus. Cancer Res. 2015; 75: 3156-3166.
32. Bosse KR, Diskin SJ, Cole KA, et al., Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 2012; 72: 2068-2078.
33. Pandey GK, Mitra S, Subhash S, et al., The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell. 2014; 26: 722-737.
34. Oldridge D, Wood AC, Crimmins I, et al., Genetic predisposition to neuroblastoma mediated by a LMO1 oncogene super-enhancer polymorphism. Nature. In press.
35. Barone G, Anderson J, Pearson AD, Petrie K, Chesler L,. New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK. Clin Cancer Res. 2013; 19: 5814-5821.
36. George RE, Sanda T, Hanna M, et al., Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008; 455: 975-978.
37. Chen Y, Takita J, Choi YL, et al., Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008; 455: 971-974.
38. Carpenter EL, Mosse YP,. Targeting ALK in neuroblastoma-preclinical and clinical advancements. Nat Rev Clin Oncol. 2012; 9: 391-399.
39. Sausen M, Leary RJ, Jones S, et al., Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2013; 45: 12-17.
40. Pugh TJ, Morozova O, Attiyeh EF, et al., The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45: 279-284.
41. Molenaar JJ, Koster J, Zwijnenburg DA, et al., Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483: 589-593.
42. Cheung NK, Zhang J, Lu C, et al., Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012; 307: 1062-1071.
43. Knudson AG Jr, Strong LC,. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet. 1972; 24: 514-532.
44. Knudson AG Jr,. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68: 820-823.
45. Bresler SC, Weiser DA, Huwe PJ, et al., ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014; 26: 682-694.
46. de Pontual L, Kettaneh D, Gordon CT, et al., Germline gain-of-function mutations of ALK disrupt central nervous system development. Hum Mutat. 2011; 32: 272-276.
47. Mosse YP, Lim MS, Voss SD, et al., Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14: 472-480.
48. Raabe EH, Laudenslager M, Winter C, et al., Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene. 2008; 27: 469-476.
49. Amiel J, Laudier B, Attie-Bitach T, et al., Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet. 2003; 33: 459-461.
50. Origone P, Defferrari R, Mazzocco K, Lo Cunsolo C, De Bernardi B, Tonini GP,. Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A. 2003; 118A: 309-313.
51. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS,. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet. 2011; 157C: 83-89.
52. Mutesa L, Pierquin G, Janin N, et al., Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors. Cancer Genet Cytogenet. 2008; 182: 40-42.
53. Birch JM, Alston RD, McNally RJ, et al., Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20: 4621-4628.
54. Tatton-Brown K, Murray A, Hanks S, et al., Weaver syndrome and EZH2 mutations: clarifying the clinical phenotype. Am J Med Genet A. 2013; 161A: 2972-2980.
55. Schimke RN, Collins DL, Stolle CA,. Paraganglioma, neuroblastoma, and a SDHB mutation: resolution of a 30-year-old mystery. Am J Med Genet A. 2010; 152A: 1531-1535.
56. Molenaar JJ, Domingo-Fernandez R, Ebus ME, et al., LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet. 2012; 44: 1199-1206.
57. Stacey SN, Sulem P, Jonasdottir A, et al., A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011; 43: 1098-1103.
58. Maris JM, Morton CL, Gorlick R, et al., Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010; 55: 26-34.
59. Bourdon JC, Fernandes K, Murray-Zmijewski F, et al., p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005; 19: 2122-2137.
60. Hosoi G, Hara J, Okamura T, et al., Low frequency of the p53 gene mutations in neuroblastoma. Cancer. 1994; 73: 3087-3093.
61. Schleiermacher G, Mosseri V, London WB, et al., Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012; 107: 1418-1422.
62. Bown N, Lastowska M, Cotterill S, et al., 17q gain in neuroblastoma predicts adverse clinical outcome. UK Cancer Cytogenetics Group and the UK Children's Cancer Study Group. Med Pediatr Oncol. 2001; 36: 14-19.
63. Maris JM, Weiss MJ, Guo C, et al., Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol. 2000; 18: 1888-1899.
64. Caron H, van Sluis P, van Hoeve M, et al., Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. Nat Genet. 1993; 4: 187-190.
65. Baker DL, Schmidt ML, Cohn SL, et al., Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363: 1313-1323.
66. Bagatell R, Rumcheva P, London WB, et al., Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005; 23: 8819-8827.
67. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al., Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27: 1026-1033.
68. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, et al., Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010; 28: 3122-3130.
69. Morales La Madrid A, Nall MB, Ouyang K, et al., Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatr Blood Cancer. 2013; 60: 332-335.
70. Boeva V, Jouannet S, Daveau R, et al., Breakpoint features of genomic rearrangements in neuroblastoma with unbalanced translocations and chromothripsis [serial online]. PLoS One. 2013; 8: e72182.
71. Fransson S, Hansson M, Ruuth K, et al., Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors. Genes Chromosomes Cancer. 2015; 54: 99-109.
72. Cazes A, Louis-Brennetot C, Mazot P, et al., Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma. Cancer Res. 2013; 73: 195-204.
73. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM,. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997; 16: 2985-2995.
74. Cascon A, Robledo M,. MAX and MYC: a heritable breakup. Cancer Res. 2012; 72: 3119-3124.
75. Burkhart CA, Cheng AJ, Madafiglio J, et al., Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst. 2003; 95: 1394-1403.
76. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH,. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun. 2006; 351: 192-197.
77. Luscher B, Larsson LG,. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene. 1999; 18: 2955-2966.
78. Huang M, Weiss WA,. Neuroblastoma and MYCN [serial online]. Cold Spring Harb Perspect Med. 2013; 3: a014415.
79. Josling GA, Selvarajah SA, Petter M, Duffy MF,. The role of bromodomain proteins in regulating gene expression. Genes (Basel). 2012; 3: 320-343.
80. Filippakopoulos P, Qi J, Picaud S, et al., Selective inhibition of BET bromodomains. Nature. 2010; 468: 1067-1073.
81. Delmore JE, Issa GC, Lemieux ME, et al., BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146: 904-917.
82. Puissant A, Frumm SM, Alexe G, et al., Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3: 308-323.
83. Bandopadhayay P, Bergthold G, Nguyen B, et al., BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014; 20: 912-925.
84. Wyce A, Ganji G, Smitheman KN, et al., BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models [serial online]. PLoS One. 2013; 8: e72967.
85. White PS, Thompson PM, Seifried BA, et al., Detailed molecular analysis of 1p36 in neuroblastoma. Med Pediatr Oncol. 2001; 36: 37-41.
86. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW,. Cancer genome landscapes. Science. 2013; 339: 1546-1558.
87. Shukla N, Ameur N, Yilmaz I, et al., Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012; 18: 748-757.
88. Schleiermacher G, Javanmardi N, Bernard V, et al., Emergence of new ALK mutations at relapse of neuroblastoma. J Clin Oncol. 2014; 32: 2727-2734.
89. Eleveld TF, Oldridge DA, Bernard V, et al., Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015; 47: 864-871.
90. Molenaar JJ, Koster J, Ebus ME, et al., Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer. 2012; 51: 10-19.
91. Rader J, Russell MR, Hart LS, et al., Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013; 19: 6173-6182.
92. Gogolin S, Ehemann V, Becker G, et al., CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle. 2013; 12: 1091-1104.
93. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN,. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer. 2003; 36: 242-249.
94. Carr-Wilkinson J, O'Toole K, Wood KM, et al., High frequency of p53/MDM2/p14ARF pathway abnormalities in relapsed neuroblastoma. Clin Cancer Res. 2010; 16: 1108-1118.
95. Omura-Minamisawa M, Diccianni MB, Chang RC, et al., p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res. 2001; 7: 3481-3490.
96. Chen L, Rousseau RF, Middleton SA, et al., Preclinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015; 6: 10207-10221.
97. Gamble LD, Kees UR, Tweddle DA, Lunec J,. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene. 2012; 31: 752-763.
98. Van Maerken T, Rihani A, Dreidax D, et al., Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol Cancer Ther. 2011; 10: 983-993.
99. Heaphy CM, de Wilde RF, Jiao Y, et al., Altered telomeres in tumors with ATRX and DAXX mutations [serial online]. Science. 2011; 333: 425.
100. Kurihara S, Hiyama E, Onitake Y, Yamaoka E, Hiyama K,. Clinical features of ATRX or DAXX mutated neuroblastoma. J Pediatr Surg. 2014; 49: 1835-1838.
101. Lundberg G, Sehic D, Lansberg JK, et al., Alternative lengthening of telomeres-an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas. Genes Chromosomes Cancer. 2011; 50: 250-262.
102. Nowell PC,. The clonal evolution of tumor cell populations. Science. 1976; 194: 23-28.
103. Mora J, Cheung NK, Gerald WL,. Genetic heterogeneity and clonal evolution in neuroblastoma. Br J Cancer. 2001; 85: 182-189.
104. Gotoh T, Sugihara H, Matsumura T, Katsura K, Takamatsu T, Sawada T,. Human neuroblastoma demonstrating clonal evolution in vivo. Genes Chromosomes Cancer. 1998; 22: 42-49.
105. Bohm N, Lampert F,. DNA-ploidy and proliferation in metastatic neuroblastoma [article in German]. Klin Padiatr. 1982; 194: 270-274.
106. Wei JS, Johansson P, Chen L, et al., Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma [serial online]. PLoS One. 2013; 8: e77731.
107. Martinsson T, Eriksson T, Abrahamsson J, et al., Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res. 2011; 71: 98-105.
108. Bentires-Alj M, Paez JG, David FS, et al., Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004; 64: 8816-8820.
109. Holzel M, Huang S, Koster J, et al., NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010; 142: 218-229.
110. Sidell N, Altman A, Haussler MR, Seeger RC,. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res. 1983; 148: 21-30.
111. Matthay KK, Villablanca JG, Seeger RC, et al., Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 1165-1173.
112. Helson L, Helson C,. Human neuroblastoma cells and 13-cis-retinoic acid. J Neurooncol. 1985; 3: 39-41.
113. Molenaar JJ, Ebus ME, Koster J, et al., Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res. 2008; 68: 2599-2609.
114. Krasnoselsky AL, Whiteford CC, Wei JS, et al., Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene. 2005; 24: 1533-1541.
115. Thompson PM, Maris JM, Hogarty MD, et al., Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res. 2001; 61: 679-686.
116. Easton J, Wei T, Lahti JM, Kidd VJ,. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res. 1998; 58: 2624-2632.
117. Cole KA, Huggins J, Laquaglia M, et al., RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A. 2011; 108: 3336-3341.
118. Caren H, Erichsen J, Olsson L, et al., High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene [serial online]. BMC Genomics. 2008; 9: 353.
119. Beiske K, Burchill SA, Cheung IY, et al., Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer. 2009; 100: 1627-1637.
120. Crystal AS, Shaw AT, Sequist LV, et al., Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014; 346: 1480-1486.
121. Diaz LA Jr, Bardelli A,. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32: 579-586.
122. Bettegowda C, Sausen M, Leary RJ, et al., Detection of circulating tumor DNA in early- and late-stage human malignancies [serial online]. Sci Transl Med. 2014; 6: 224ra24.
123. Kojima M, Hiyama E, Fukuba I, et al., Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma. Pediatr Surg Int. 2013; 29: 1139-1145.
124. Gotoh T, Hosoi H, Iehara T, et al., Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction. J Clin Oncol. 2005; 23: 5205-5210.
125. Combaret V, Brejon S, Iacono I, et al., Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer. 2011; 56: 757-761.
126. Combaret V, Iacono I, Bellini A, et al., Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med. 2015; 4: 540-550.